185 related articles for article (PubMed ID: 17784727)
1. Folate-targeted dinitrophenyl hapten immunotherapy: effect of linker chemistry on antitumor activity and allergic potential.
Lu Y; You F; Vlahov I; Westrick E; Fan M; Low PS; Leamon CP
Mol Pharm; 2007; 4(5):695-706. PubMed ID: 17784727
[TBL] [Abstract][Full Text] [Related]
2. Low-dose radiation potentiates the therapeutic efficacy of folate receptor-targeted hapten therapy.
Sega EI; Lu Y; Ringor M; Leamon CP; Low PS
Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):559-66. PubMed ID: 18411004
[TBL] [Abstract][Full Text] [Related]
3. Folate targeting enables durable and specific antitumor responses from a therapeutically null tubulysin B analogue.
Leamon CP; Reddy JA; Vetzel M; Dorton R; Westrick E; Parker N; Wang Y; Vlahov I
Cancer Res; 2008 Dec; 68(23):9839-44. PubMed ID: 19047164
[TBL] [Abstract][Full Text] [Related]
4. Folate-targeted hapten immunotherapy of adjuvant-induced arthritis: comparison of hapten potencies.
Yi YS; Ayala-López W; Kularatne SA; Low PS
Mol Pharm; 2009; 6(4):1228-36. PubMed ID: 19374407
[TBL] [Abstract][Full Text] [Related]
5. Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential.
Lu Y; Sega E; Leamon CP; Low PS
Adv Drug Deliv Rev; 2004 Apr; 56(8):1161-76. PubMed ID: 15094213
[TBL] [Abstract][Full Text] [Related]
6. Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors.
Lu Y; Low PS
Cancer Immunol Immunother; 2002 May; 51(3):153-62. PubMed ID: 11941454
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of an in vitro method for the measurement of specific IgE antibody responses: the rat basophilic leukemia (RBL) cell assay.
Dearman RJ; Skinner RA; Deakin N; Shaw D; Kimber I
Toxicology; 2005 Jan; 206(2):195-205. PubMed ID: 15588913
[TBL] [Abstract][Full Text] [Related]
8. Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate.
Reddy JA; Westrick E; Santhapuram HK; Howard SJ; Miller ML; Vetzel M; Vlahov I; Chari RV; Goldmacher VS; Leamon CP
Cancer Res; 2007 Jul; 67(13):6376-82. PubMed ID: 17616697
[TBL] [Abstract][Full Text] [Related]
9. Folate-targeted enzyme prodrug cancer therapy utilizing penicillin-V amidase and a doxorubicin prodrug.
Lu JY; Lowe DA; Kennedy MD; Low PS
J Drug Target; 1999; 7(1):43-53. PubMed ID: 10614814
[TBL] [Abstract][Full Text] [Related]
10. Strategy to prevent drug-related hypersensitivity in folate-targeted hapten immunotherapy of cancer.
Lu Y; Klein PJ; Westrick E; Xu LC; Santhapuram HK; Bloomfield A; Howard SJ; Vlahov IR; Ellis PR; Low PS; Leamon CP
AAPS J; 2009 Sep; 11(3):628-38. PubMed ID: 19728104
[TBL] [Abstract][Full Text] [Related]
11. Folate receptor-targeted immunotherapy: induction of humoral and cellular immunity against hapten-decorated cancer cells.
Lu Y; Sega E; Low PS
Int J Cancer; 2005 Sep; 116(5):710-9. PubMed ID: 15828051
[TBL] [Abstract][Full Text] [Related]
12. Reductively aminated D-xylose-albumin conjugate as the immunogen for generation of IgG and IgE antibodies specific to D-xylitol, a haptenic allergen.
Sreenath K; Venkatesh YP
Bioconjug Chem; 2007; 18(6):1995-2003. PubMed ID: 17979222
[TBL] [Abstract][Full Text] [Related]
13. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
14. Impact of high and low folate diets on tissue folate receptor levels and antitumor responses toward folate-drug conjugates.
Leamon CP; Reddy JA; Dorton R; Bloomfield A; Emsweller K; Parker N; Westrick E
J Pharmacol Exp Ther; 2008 Dec; 327(3):918-25. PubMed ID: 18791065
[TBL] [Abstract][Full Text] [Related]
15. Folate receptor specific anti-tumor activity of folate-mitomycin conjugates.
Reddy JA; Westrick E; Vlahov I; Howard SJ; Santhapuram HK; Leamon CP
Cancer Chemother Pharmacol; 2006 Aug; 58(2):229-36. PubMed ID: 16331500
[TBL] [Abstract][Full Text] [Related]
16. Effect on tolerance induction of the mode of attachment of the hapten the carrier.
Paley RS; Leskowitz S; Borel Y
J Immunol; 1975 Nov; 115(5):1409-13. PubMed ID: 1100732
[TBL] [Abstract][Full Text] [Related]
17. [Folate receptor-mediated antitumor drugs].
Zhao J; Cao SL; Zheng XL; Zhao B
Yao Xue Xue Bao; 2009 Feb; 44(2):109-14. PubMed ID: 19408677
[TBL] [Abstract][Full Text] [Related]
18. Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts.
Yoshizawa T; Hattori Y; Hakoshima M; Koga K; Maitani Y
Eur J Pharm Biopharm; 2008 Nov; 70(3):718-25. PubMed ID: 18647651
[TBL] [Abstract][Full Text] [Related]
19. In vivo structural activity and optimization studies of folate-tubulysin conjugates.
Reddy JA; Dorton R; Dawson A; Vetzel M; Parker N; Nicoson JS; Westrick E; Klein PJ; Wang Y; Vlahov IR; Leamon CP
Mol Pharm; 2009; 6(5):1518-25. PubMed ID: 19630399
[TBL] [Abstract][Full Text] [Related]
20. Combination cancer therapy by hapten-targeted prodrug-activating enzymes and cytokines.
Chuang KH; Cheng CM; Roffler SR; Lu YL; Lin SR; Wang JY; Tzou WS; Su YC; Chen BM; Cheng TL
Bioconjug Chem; 2006; 17(3):707-14. PubMed ID: 16704208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
